专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140303176A1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR 有权
标题翻译：适用于治疗多巴胺D3受体调节障碍的ACYLAMINOCOCLOALKYL化合物
公开(公告)号：US20140303176A1
公开(公告)日：2014-10-09
申请号：US14213169
申请日：2014-03-14
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Andreas HAUPT , Jürgen DINGES , Liliane UNGER , Karsten WICKE , Robert VAN WATERSCHOOT , Karla DRESCHER , Ana RELO
IPC分类号： C07D295/155
CPC分类号： C07D295/155 , A61K31/496 , C07D239/42 , C07D403/04
摘要： The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH2, CH2CH2, CHFCH2 and CF2CH2, R1 is an oxygen containing cyclic radical selected such as C3-C6 cycloalkyl, which carries one or two oxygen containing radicals selected from the group consisting of OH, C1-C2-alkoxy, fluorinated C1-C2-alkoxy, and a carbonyl oxygen, R2 is selected from the group consisting of hydrogen, OH and fluorine, R3a is selected from the group consisting of hydrogen and methyl, R3b is selected from the group consisting of hydrogen and methyl, R4 is branched C4-C6 alkyl or branched fluorinated C4-C6 alkyl, and R5 is inter alia C1-C6 alkyl, fluorinated C1-C3 alkyl, C1-C2-alkoxy-C1-C4-alkyl, fluorinated C1-C2-alkoxy-C1-C4-alkyl, hydroxy-C1-C4-alkyl, fluorinated hydroxy-C1-C4-alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C3-C5 cycloalkyl, fluorinated C3-C5 cycloalkyl, etc.
摘要翻译：本发明涉及新的酰氨基环烷基化合物，特别是涉及本文所述的式I化合物及其盐和N-氧化物。该化合物具有有价值的治疗特性，特别适用于治疗对多巴胺D3受体调节作出反应的疾病。在式I中，变量具有以下含义：m为1或2，n为1或2，A选自CH 2，CH 2 CH 2，CHFCH 2和CF 2 CH 2，R 1为选自氧的环状基团，例如C 3 -C 6环烷基，其携带一个或两个选自OH，C 1 -C 2烷氧基，氟化C 1 -C 2烷氧基和羰基氧的含氧基团，R 2选自氢，OH和氟，R 3a选自氢和甲基，R 3b选自氢和甲基，R 4是支链C 4 -C 6烷基或支链氟化C 4 -C 6烷基，R 5尤其是C 1 -C 6烷基氟化C 1 -C 3烷基，C 1 -C 2烷氧基-C 1 -C 4烷基，氟化C 1 -C 2烷氧基-C 1 -C 4 - 烷基，羟基-C 1 -C 4 - 烷基，氟化羟基-C 1 -C 4烷基，氧杂环丁烷基，氟化氧杂环丁烷基，氧杂环戊烷基，氟代氧杂环戊烷基，C3-C5环烷基，氟化C3-C5环烷基等

2. 发明申请

US20140275104A1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR 有权
公开(公告)号：US20140275104A1
公开(公告)日：2014-09-18
申请号：US14213720
申请日：2014-03-14
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Andreas HAUPT , Jürgen DINGES , Liliane UNGER , Karsten WICKE , Robert VAN WATERSCHOOT , Karla DRESCHER , Ana RELO
IPC分类号： C07D239/42
CPC分类号： C07D239/42 , A61K31/506 , C07D403/04
摘要： The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH2, CH2CH2, CHFCH2 and CF2CH2, R1 is an oxygen containing cyclic radical selected such as C3-C6 cycloalkyl, which carries one or two oxygen containing radicals selected from the group consisting of OH, C1-C2-alkoxy, fluorinated C1-C2-alkoxy, and a carbonyl oxygen, R2 is selected from the group consisting of hydrogen, OH and fluorine, R3a is selected from the group consisting of hydrogen and methyl, R3b is selected from the group consisting of hydrogen and methyl, R4 is branched C4-C6 alkyl or branched fluorinated C4-C6 alkyl, and R5 is inter alia C1-C6 alkyl, fluorinated C1-C3 alkyl, C1-C2-alkoxy-C1-C4-alkyl, fluorinated C1-C2-alkoxy-C1-C4-alkyl, hydroxy-C1-C4-alkyl, fluorinated hydroxy-C1-C4-alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C3-C5 cycloalkyl, fluorinated C3-C5 cycloalkyl, etc.

3. 发明申请

US20170260158A1 QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 审中-公开
公开(公告)号：US20170260158A1
公开(公告)日：2017-09-14
申请号：US15458534
申请日：2017-03-14
申请人： Abbvie Deutschland GmbH & Co. KG
发明人： Hervé GENESTE , Andreas HAUPT , Frauke POHLKI , Ana Lucia RELO , Liliane UNGER , Karsten WICKE
IPC分类号： C07D401/04 , C07D401/14
CPC分类号： C07D401/04 , C07D401/12 , C07D401/14
摘要： The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.

4. 发明申请

US20190135777A1 QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR 审中-公开
公开(公告)号：US20190135777A1
公开(公告)日：2019-05-09
申请号：US16229723
申请日：2018-12-21
申请人： AbbVie Deutschland GmbH & Co. KG
发明人： Hervé GENESTE , Andreas HAUPT , Frauke POHLKI , Ana Lucia RELO , Liliane UNGER , Karsten WICKE
IPC分类号： C07D401/04 , C07D401/12 , C07D401/14
摘要： The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式